Quarterly Report III 21/22
September 2021 – May 2022, Diamyd Medical AB (publ), Fiscal year 2021/2022Developing Precision Medicine Therapies for Type 1 DiabetesDiamyd Medical’s B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B.Further information is available on https://www.diamyd.com September 1, 2021 – May 31, 2022 · Net result: MSEK -63.4 (87.3), third quarter: MSEK -17.1 (-32.7). The previous year includes a one-off effect of corresponding MSEK 144.4 from divestment of shares in Companion Medical, Inc. · Result per share: SEK -0.8 (1.3), third quarter: SEK –0.2 (-0.5)